IR Information
IR Information
News Release
News release
-
2025.06.05
Partial correction of the contents of the” Announcement of the 23rd Ordinary General Meeting of Shareholders”
(240KB)
-
2025.06.05
Announcement of the 23rd Ordinary General Meeting of Shareholders
(5MB)
-
2025.05.29
Announcement of our CEO’s appointment as a director of the SAMURAI Biotech Association
(243KB)
-
2025.05.28
Report on the International Seminar Held at the 78th Annual Meeting of the Japanese Society for Oxidative Stress Research
(331KB)
-
2025.05.21
Meeting with Mr. Tse Ping, founder of Sino Biopharmaceutical Limited and Vice Chairman of our Board of Directors, and our CEO
(261KB)
Financial Information
Disclosure
Financial Results
| 21st Fiscal Period (Results for March 2023) | |
|---|---|
| Net sales (Thousands of yen) | 15,271 |
| Operating income (thousand yen) | 81,000 |
| Net income (thousand yen) | 70,254 |
| Net assets (Thousands of yen) | 4,002,480 |
| Total assets (Thousands of yen) | 4,214,922 |
| Equity ratio (%) | 94.9 |
Business Report
Business report
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
19th Term
Business Overview
(595KB)
18th Term
Business Overview
(527KB)
17th Term
Business Overview
(521KB)
